We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Dec 2020 - 08 Dec 2020
Virtual Venue
07 Dec 2020 - 11 Dec 2020

Immune Cells Hampered Fighting Soft Tissue and Bone Sarcomas

By LabMedica International staff writers
Posted on 06 Jul 2020
Print article
Image: Aggregates of immune cells known as tertiary lymphoid structures (TLSs), seen here within a tumor of the soft tissues known as a rhabdomyosarcoma, are major players in the immune system’s fight against cancer (Photo courtesy of Johns Hopkins Kimmel Cancer Center).
Image: Aggregates of immune cells known as tertiary lymphoid structures (TLSs), seen here within a tumor of the soft tissues known as a rhabdomyosarcoma, are major players in the immune system’s fight against cancer (Photo courtesy of Johns Hopkins Kimmel Cancer Center).
Immunotherapies such as checkpoint inhibitors that enhance the body's natural ability to fight cancer have been only minimally successful in treating sarcomas which are rare cancers that grow in the soft tissues and bones.

There are many subtypes of sarcoma, which are classified based on the specific tissue and type of cell from which the tumor originates. Sarcomas are primary connective tissue tumors, meaning that they arise in connective tissues. This is in contrast to secondary (or "metastatic") connective tissue tumors, which occur when a cancer from elsewhere in the body (such as the lungs, breast tissue or prostate) spreads to the connective tissue.

Oncologists at the Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) and their numerous colleagues interrogated the tumor microenvironment (TME) of two contrasting soft-tissue sarcomas (STS), rhabdomyosarcomas and undifferentiated pleomorphic sarcomas (UPS), with differing genetic underpinnings and responses to immune checkpoint inhibition to understand the mechanisms that lead to response. The team used fresh and formalin-fixed, paraffin-embedded tissue from patients diagnosed with UPS and rhabdomyosarcomas, and dissected the TME by using immunohistochemistry (IHC), flow cytometry, and comparative transcriptomic studies.

The investigators discovered that both tumor types were ripe with tumor-associated macrophages (TAMs). Heavily involved in promoting tumor initiation and growth, TAMs hamper the proper immune reaction against tumors. Additionally, both sarcomas had similar amounts of CD8+ T lymphocytes (CD 8+ T cells are also known as "killer T cells"), immune system cells that protect the body from infection and are believed to be among the front-line soldiers in the fight against cancers. They also discovered that where the CD8+ T cells congregated and how their antitumor functions were impeded by TAMs differed in the two sarcomas.

In UPS, the group found that the tumors themselves were filled with TAMs and CD8+ T cells. With constant stimulation by tumor antigens, CD8+ cells produce large amounts of PD-1, a protein that eventually exhausts the T cell population. When this happens, the authors suggest, and TAMs control the environment, normal T cell activity against the cancer is suppressed. In rhabdomyosarcomas, they found CD8+ T cells only within tiny aggregates of immune cells called tertiary lymphoid structures (TLSs). TLSs are known to play a major role in initiating antitumor immune responses, helping the immune system recognize cancer cells as targets.

Nicolas Llosa, MD, an assistant professor of oncology and senior author of the study said, “The basis of successful immunotherapy lies in the ability of the immune system to recognize cancer as foreign and attack, and is dependent on genetics, host and environmental factors, and makeup of the tumor microenvironment. We need to understand the immune niche that sustains these tumors and how it supports tolerance, so we can determine what drug targets could be used to help mount a better response.”

The authors concluded that their work in soft tissue sarcomas revealed an immunosuppressive TME dominated by myeloid cells, which may be overcome with activation of T cells that traffic into the tumor. In rhabdomyosarcomas, targeting T cells found within TLS may be crucial to achieve antitumor response. The study was published on June 16, 2020 in the journal Clinical Cancer Research.

Related Links:
Johns Hopkins Kimmel Cancer Center


Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.